



**In-Cell-Art invited to present at two conferences: (1) Messenger RNA therapeutics: advances and perspectives on March 22<sup>nd</sup> and 23<sup>rd</sup> March 2017 and (2) Innovative Clinical Research Network in Vaccinology on March 24<sup>th</sup> 2017.**

**Nantes – France, 20<sup>th</sup> of March, 2017** – In-Cell-Art (ICA), a biotechnology company specializing in nanocarrier technologies named Nanotaxi® for unlocking the promise of nucleic acids to treat acquired or inherited diseases, announces today the presentation at two conferences: (1) Messenger RNA therapeutics: advances and perspectives in Orléans on 22<sup>nd</sup> and 23<sup>rd</sup> of March, 2017, and (2) Innovative Clinical Research Network in Vaccinology in Paris on 24<sup>th</sup> of March, 2017.

The presentations of In-Cell-Art in these conferences where leading international researchers will participate, reflect on ICA expertise to develop new classes of vaccines and therapies using Nucleic acids molecules delivered by Nanotaxi®. During these two conferences, In-Cell-Art will have opportunities to introduce the results on the breakthrough discovery of bioinspired delivery systems for mRNA vaccines and medicines and the results of independent research project about ZIKA vaccination.

Bruno Pitard, one of founders of In-Cell-Art, comments *"In-Cell-Art presence in the invited speakers of those two conferences is a great honor. This is the recognition for the solid and strong innovative research and development activity establishing today In-Cell-Art as a leading company to use all the potential of nucleic acid for development of innovative vaccines and medicines"*.

### **About In-Cell-Art**

In-Cell-Art (ICA), which is headquartered in Nantes (France) is a biopharmaceutical company specializing in the preclinical and pharmaceutical development of nanocarriers named Nanotaxi ® for macromolecular drugs. Its founder and research team, which includes a Nobel Laureate, have designed new classes of vectors that are organized on a nanometric scale, which enables them to cross the cell barrier efficiently and safely. In-Cell-Art offers a range of reagents and biotechnology development services:

#### **1. ICANTibodies™**

In the absence of recombinant antigen, ICANTibodies™ allows, from an in silico DNA antigenic sequence, the production of the most ambitious functional antibodies against any natively expressed nuclear, cytoplasmic, secreted or membrane proteins. ICANTibodies™ has allowed, in less than 3 years, the production of more than 300 different functional antibodies. In-Cell-Art has worked with a number of pharmaceutical firms (Sanofi,

GlaxoSmithKline, Geneuro etc.) and public research institutions and universities (Institut Cochin, Cancer Research UK, Institute of Neurology UK etc).

## **2. ICA Nanotaxi®**

- DNA Vaccine

ICA614 Nanotaxi®, an innovative DNA synthetic formulation, offers unique efficient and industrial features such as the dramatic enhancement of the immunogenicity of plasmid DNA-encoding tumours or pathogen-derived antigens, a reduction in the dose of plasmid DNA, as well as an excellent safety profile. ICA614 Nanotaxi® represents a crucial step in DNA vaccine development, and is currently being tested by major vaccine companies.

- mRNA Vaccine

Some other ICA Nanotaxi® are also being assessed in \$33.1 million RN-ARMORVAX consortium, co-funded by US Defense Advanced Research Projects Agency (DARPA). The consortium would validate the new application of ICA Nanotaxi® for mRNA-based vaccines for infectious diseases in collaboration with CureVac and Sanofi-Pasteur.

- mRNA Replacement Therapy

Some other ICA Nanotaxi® are also developed to improve the limited efficacy and stability of mRNA therapeutics, leading to the dramatic increase in therapeutic protein expression without DNA-encoded gene.

## **3. ICAFectin® transfection reagents**

ICAFectin® transfection reagents are innovative breakthrough synthetic vectors for in vitro nucleic acid delivery. They are becoming the reagents of choice for efficient DNA and siRNA transfections as demonstrated by their increasing use in numerous studies published in high impact factor journals including Journal of Biological Chemistry, Nucleic Acids Research, PLOS ONE, PLOS Pathogen, Human Gene Therapy, Cell reports, EMBO Jand more.

In-Cell-Art is a privately held company, which was founded in 2005. It is a member of the Atlanpole Biotherapies high-tech cluster of biotechnology companies in western France.

For further information please contact;

In-Cell-Art

Tel: 33 (0)6 73 19 12 02

E-mail: [info@incellart.com](mailto:info@incellart.com)

Website : <http://www.incellart.com>